These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 6784924

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV.
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [Abstract] [Full Text] [Related]

  • 3. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
    Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH.
    Cancer Clin Trials; 1980 Jul; 3(1):23-7. PubMed ID: 7190082
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
    Numico G, Benasso M, Vannozzi MO, Merlano M, Rosso R, Viale M, Esposito M.
    Anticancer Res; 1998 Jul; 18(2B):1313-8. PubMed ID: 9615808
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB, Kalman SM, Jacobs C.
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [Abstract] [Full Text] [Related]

  • 9. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL, Reed E.
    Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.
    Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B.
    Cancer Res; 1986 Nov; 46(11):5969-72. PubMed ID: 3756934
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study.
    Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, Giammanco M, Sarullo FM, Licata G.
    J Am Coll Cardiol; 2005 Jun 21; 45(12):1997-2003. PubMed ID: 15963399
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).
    Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ.
    Cancer Treat Rep; 1979 Jun 21; 63(9-10):1515-21. PubMed ID: 498151
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT, Fels LM, Franzke A, Knop S, Renn M, Maess B, Panagiotou P, Lampe H, Kanz L, Stolte H, Bokemeyer C.
    Anticancer Res; 2000 Jun 21; 20(5C):3767-73. PubMed ID: 11268452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.